Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Nanda K, Moss AC.Clinical Pharmacology: Advances and Applications. 2012, 4:41–50.The authors apologize for errors on Tables 1, 2, and 3.Table1Citation 40, Hussain et al, should have been citation 44, Shire US Inc.Table 2Lichtenstein et al data, the confidence interval (CI) of the odds...
Saved in:
Main Authors: | Nanda K, Moss AC |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/03009643a99b4fe0be7bb0f9e8f3d55c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
by: Nanda K, et al.
Published: (2012) -
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
by: Maconi G, et al.
Published: (2021) -
Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis
by: Peishan Qiu, et al.
Published: (2021) -
Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
by: Jakate A, et al.
Published: (2019) -
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)
by: Bartosh NS, et al.
Published: (2013)